脉君安片联合缬沙坦治疗中老年原发性高血压的临床研究

Clinical study on Maijunan Tablets combined with valsartan in treatment of middle-aged and elderly patients with essential hypertension

目的探讨脉君安片联合缬沙坦胶囊治疗中老年原发性高血压的临床疗效。方法选择2021年2月—2021年6月在天津市红桥医院治疗的102例原发性高血压老年患者,根据用药的差别分为对照组和治疗组,每组各51例。对照组口服缬沙坦胶囊,80mg/次,1次/d;治疗组在对照组基础上口服脉君安片,1.5g/次。3次/d。两组患者均经4周治疗。观察两组患者临床疗效,比较治疗前后两组血压水平,证候改善时间,及血清单核细胞趋化蛋白1(MCP-1)、同型半胱氨酸(Hcy)、基质金属蛋白酶-9(MMP-9)、降钙素基因相关肽(CGRP)、人可溶性细胞黏附分子(sICAM-1)和血管性假血友病因子(vWF)水平。结果经治疗,对照组和治疗组总有效率分别为84.31%和98.04%,差异有统计学意义(P<0.05)。经治疗,两组SBP(收缩压)、DBP(舒张压)较治疗前均显著下降(P<0.05),且治疗组改善更明显(P<0.05)。经治疗,治疗组患者头晕、头痛、心烦、耳鸣等症状改善时间均早于对照组(P<0.05)。经治疗,两组血清MCP-1、Hcy、MMP-9、CGRP、sICAM-1、v WF水平均明显降低(P<0.05),且治疗组下降更显著(P<0.05)。结论脉君安片联合缬沙坦胶囊治疗中老年原发性高血压不仅促进血压下降,还能够促进机体细胞因子和临床症状的改善。

Objective To investigate the clinical efficacy of Maijunan Tablets combined with valsartan in treatment of middle-aged and elderly patients with essential hypertension.Methods Patients(102 cases)with essential hypertension in Tianjin Hongqiao Hospital from February 2021 to June 2021 were divided into control and treatment group according to different treatments,and each group had 51 cases.Patients in the control group were po administered with Valsartan Capsules,80 mg/time,once daily.Patients in the treatment group were po administered with Maijunan Tablets on the basis of the control group,1.5 g/time,three times daily.Patients in two groups were treated for 4 weeks.After treatment,the clinical evaluation was evaluated,the blood pressure,the improvement time of symptom,and the levels of serological indexes MCP-1,Hcy,MMP-9,CGRP,sICAM-1 and vWF in two groups before and after treatment were compared.Results After treatment,the effective rates of the control group and the treatment group were 84.31%and 98.04%,respectively(P<0.05).After treatment,the levels of SBP and DBP in two groups were significantly lower than those before treatment(P<0.05),and the improvement in the treatment group was more obvious(P<0.05).After treatment,the improvement time of dizziness,headache,annoyance and tinnitus in the treatment group was earlier than that in the control group(P<0.05).After treatment,the levels of serum MCP-1,Hcy,MMP-9,CGRP,sICAM-1 and vWF were significantly decreased in two groups(P<0.05),especially in the treatment group(P<0.05).Conclusion Maijunan Tablets combined with valsartan in treatment of middle-aged and elderly patients with essential hypertension can not only promote the decrease of blood pressure,but also improve the cytokines and clinical symptoms.